VERTEX PHARMACEUTICALS INC / MA·4

Mar 3, 4:25 PM ET

Bozic Carmen 4

4 · VERTEX PHARMACEUTICALS INC / MA · Filed Mar 3, 2026

Research Summary

AI-generated summary of this filing

Updated

Vertex (VRTX) CMO Carmen Bozic Sells 2,329 Shares

What Happened

  • Carmen Bozic, EVP and Chief Medical Officer of Vertex Pharmaceuticals (VRTX), sold 2,329 shares on 2026-02-27 at $480.31 per share, generating proceeds of approximately $1,118,642. The Form 4 lists the transaction as a sale (S), described as an open-market or private sale.

Key Details

  • Transaction date and price: 2026-02-27 at $480.31 per share
  • Shares sold / proceeds: 2,329 shares for ~$1,118,642
  • Filing date / timeliness: Form 4 filed 2026-03-03 for a report period of 2026-02-27 — filing appears timely
  • Shares owned after transaction: Not specified in the provided filing
  • Footnote: Transaction executed pursuant to a company-approved Rule 10b5-1 trading plan entered 11/20/2025 (preplanned sale)

Context

  • Sales under a 10b5-1 plan are prearranged and routine; they do not necessarily signal a change in the insider’s view of the company. For retail investors, purchases typically carry more interpretive weight than routine sales.

Insider Transaction Report

Form 4
Period: 2026-02-27
Bozic Carmen
EVP and CMO
Transactions
  • Sale

    Common Stock

    [F1]
    2026-02-27$480.31/sh2,329$1,118,64237,734 total
Footnotes (1)
  • [F1]Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025.
Signature
/s/ Christiana Stevenson, Attorney-in-Fact|2026-03-03

Documents

1 file
  • 4
    wk-form4_1772573117.xmlPrimary

    FORM 4